RxDoctor Payments DataLook up a doctor →

Mary Hobbs-Maluccio, MD

Surgical Oncology · Metairie, LANPI 1477505071

Payments from drug & device makers

$232,297in general payments, 2019–2025

Across 192 payments — averaging $1209.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$164K
  • Advanced Accelerator Applications$30K
  • Novartis$28K
  • Histosonics, Inc.$6K
  • Johnson & Johnson$392
  • Exelixis Inc.$390
  • plus $4K from 46 others
$841in research payments, 2019–2025

Across 4 payments — averaging $210.23 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis Pharma AG$841

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$232,297 in reported general payments places this provider in the 95th percentile of 26 surgical oncology providers in Louisiana.

See all surgical oncology providers in Louisiana

Medicare billing

Part B allowed, 2024
$55,267
Medicare patients
154
Services billed
383

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other surgical oncology in Metairie

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →